Difluprednate: An Overview

The mainstay in the treatment of ocular inflammation, either post-surgical or endogenous, is the use of steroids. While these agents effectively address inflammation, they are not without their risks, including ocular hypertension and acceleration of cataract formation. The most notorious culprits a...

Full description

Saved in:
Bibliographic Details
Main Authors: Charu Mithal, Shilpa Singh, Sonali Gupta, Sandeep Mithal
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Delhi Journal of Ophthalmology
Subjects:
Online Access:https://journals.lww.com/10.7869/djo.2012.63
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849314349033717760
author Charu Mithal
Shilpa Singh
Sonali Gupta
Sandeep Mithal
author_facet Charu Mithal
Shilpa Singh
Sonali Gupta
Sandeep Mithal
author_sort Charu Mithal
collection DOAJ
description The mainstay in the treatment of ocular inflammation, either post-surgical or endogenous, is the use of steroids. While these agents effectively address inflammation, they are not without their risks, including ocular hypertension and acceleration of cataract formation. The most notorious culprits are the strong steroids, such as prednisolone acetate and betamethasone. This review aims to cover the biochemistry and drug development of difluprednate, a novel synthetic strong steroid emulsion. In vivo pharmacokinetics as well as ocular distribution and metabolism are discussed, followed by a comprehensive summary of phase I, II, and III clinical trials evaluating safety and efficacy in patients suffering from postoperative inflammation, posterior segment inflammation or anterior uveitis.
format Article
id doaj-art-38f7a2d9aac34fd180d5afabcb010ae6
institution Kabale University
issn 0972-0200
2454-2784
language English
publishDate 2013-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Delhi Journal of Ophthalmology
spelling doaj-art-38f7a2d9aac34fd180d5afabcb010ae62025-08-20T03:52:29ZengWolters Kluwer Medknow PublicationsDelhi Journal of Ophthalmology0972-02002454-27842013-01-0123316516810.7869/djo.2012.63Difluprednate: An OverviewCharu MithalShilpa SinghSonali GuptaSandeep MithalThe mainstay in the treatment of ocular inflammation, either post-surgical or endogenous, is the use of steroids. While these agents effectively address inflammation, they are not without their risks, including ocular hypertension and acceleration of cataract formation. The most notorious culprits are the strong steroids, such as prednisolone acetate and betamethasone. This review aims to cover the biochemistry and drug development of difluprednate, a novel synthetic strong steroid emulsion. In vivo pharmacokinetics as well as ocular distribution and metabolism are discussed, followed by a comprehensive summary of phase I, II, and III clinical trials evaluating safety and efficacy in patients suffering from postoperative inflammation, posterior segment inflammation or anterior uveitis.https://journals.lww.com/10.7869/djo.2012.63difluprednatesteroidemulsionophthalmic surgery.
spellingShingle Charu Mithal
Shilpa Singh
Sonali Gupta
Sandeep Mithal
Difluprednate: An Overview
Delhi Journal of Ophthalmology
difluprednate
steroid
emulsion
ophthalmic surgery.
title Difluprednate: An Overview
title_full Difluprednate: An Overview
title_fullStr Difluprednate: An Overview
title_full_unstemmed Difluprednate: An Overview
title_short Difluprednate: An Overview
title_sort difluprednate an overview
topic difluprednate
steroid
emulsion
ophthalmic surgery.
url https://journals.lww.com/10.7869/djo.2012.63
work_keys_str_mv AT charumithal difluprednateanoverview
AT shilpasingh difluprednateanoverview
AT sonaligupta difluprednateanoverview
AT sandeepmithal difluprednateanoverview